San Diego skin cancer diagnostics startup DermTech is developing gene classifiers and expression tests to help more accurately screen for dermatologic issues.
It just raised $2.4 million to do so, according to a regulatory filing – an interesting funding notice, given its announcement last year that it was readying for – and then withdrawing – a $25 million IPO. Poor market conditions, it said. Renaissance Capital writes:
Help employers find you! Check out all the jobs and post your resume.
